The Burden and Impact of Vertigo: Findings from the REVERT Patient Registry by Heike Benecke et al.
CLINICALTRIAL ARTICLE
published: 02 October 2013
doi: 10.3389/fneur.2013.00136
The burden and impact of vertigo: findings from the
REVERT patient registry
Heike Benecke1, SamAgus2†, Daniel Kuessner 2†, Gordon Goodall 2† and Michael Strupp3*
1 Abbott Laboratories GmbH, Hannover, Germany
2 Abbott Products Operations AG, Allschwil, Switzerland
3 Department of Neurology, German Centre for Vertigo and Dizziness (IFB LMU), University Hospital Munich, Munich, Germany
Edited by:
Herman Kingma, Maastricht
University, Netherlands
Reviewed by:
Giacinto Asprella-Libonati, Madonne
delle Grazie Hospital ASM Matera,
Italy
Vincenzo Marcelli, Università degli
Studi di Napoli Federico II, Italy
*Correspondence:
Michael Strupp, Department of
Neurology, The German Dizziness
Center, University Hospital Munich,
Campus Grosshadern,
Marchioninistrasse 15, Munich 81377,
Germany
e-mail: michael.strupp@med.
uni-muenchen.de
†Present address:
Sam Agus, Shire AG, Eysins,
Switzerland;
Daniel Kuessner , Basilea
Pharmaceutica International Ltd.,
Basel, Switzerland;
Gordon Goodall , Edwards
Lifesciences SA, Nyon, Switzerland
Objective:Despite the high prevalence of vertigo globally and an acknowledged, but under-
reported, effect on an individual’s wellbeing, few studies have evaluated the burden on
healthcare systems and society. This study was aimed to quantitatively determine the
impact of vertigo on healthcare resource use and work productivity.
Methods: The economic burden of vertigo was assessed through a multi-country, non-
interventional, observational registry of vertigo patients: the Registry to Evaluate the Bur-
den of Disease in Vertigo. Patients included were those with a new diagnosis of Meniere’s
disease, benign paroxysmal positional vertigo, other vertigo of peripheral vestibular origin,
or peripheral vestibular vertigo of unknown origin.
Results: A total of 4,294 patients at 618 centers in 13 countries were included during the
registry. Of the 4,105 patients analyzed, only half were in employment. Among this work-
ing patient population, 69.8% had reduced their workload, 63.3% had lost working days,
and 4.6% had changed and 5.7% had quit their jobs, due to vertigo symptoms. Use of
healthcare services among patients was high. In the 3months preceding Visit 1, patients
used emergency services 0.4±0.9 times, primary care consultations 1.6±1.8 times, and
specialist consultations 1.4±2.0 times (all mean±SD). A mean of 2.0±5.4 days/patient
was also spent in hospital due to vertigo.
Conclusion: In addition to the negative impact on the patient from a humanistic per-
spective, vertigo has considerable impact on work productivity and healthcare resource
use.
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INTRODUCTION
Vertigo is defined as a perceived movement of either one’s own
body, such as swaying or rotation, or of the environment, or both,
in the absence of physical movement (1–3) and secondary symp-
toms include cold sweating, nausea, and vomiting (4). Vertigo and
dizziness are most often caused by different vestibular disorders,
such as benign paroxysmal positional vertigo (BPPV), Meniere’s
disease (MD), and other vertigo of peripheral vestibular origin (2,
5). Causes of vertigo are multi-faceted and can be due to a dys-
function of the peripheral or central vestibular system (2, 3), but
may also be psychogenic.
Vertigo is one of the most common conditions with which
patients present to physicians and its incidence increases with age
(3, 6, 7). Despite a lifetime prevalence of dizziness and vertigo
estimated at 20–30% and 1-year prevalence estimate for vertigo of
4.9% (8), the healthcare burden of vertigo is still relatively under-
reported due to the unpredictability of attacks and the nature of
the disease (4).
Although often perceived as a mild physical disorder with
low morbidity, the psychological impact of vertigo can lead to
a substantial impact on the individual’s lifestyle and behav-
ior (4). For example, research suggests that patients have had
to quit, change, or modify their jobs due to their symp-
toms (4) suggesting a considerable impact on quality of
life (6, 9).
Despite this, few studies have attempted to quantify the eco-
nomic burden of vertigo including the impact on work pro-
ductivity and healthcare resource use (5, 9). Of the studies that
have been published, some were constrained by the context of
a clinical trial (10), and others were small scale local-level stud-
ies where information was collected retrospectively (11). There-
fore, the objective of the Registry to Evaluate the Burden of
Disease in Vertigo (REVERT) was to help estimate the bur-
den associated with vertigo from a multi-country perspective.
In a previous publication, we reported the clinical and demo-
graphic features of the patient population included in REVERT,
before treatment and after 6 months of treatment (12). Here
we focus specifically on the economic impact on healthcare
resource use and the cost implications in terms of lost work
productivity.
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MATERIALS AND METHODS
STUDY DESIGN AND POPULATION
Data were collected through a multi-country non-interventional
registry of vertigo patients. Invitations to participate in the study
were sent to centers in 112 countries. Of these, 618 centers in 13
countries agreed to participate (Algeria, Czech Republic, Egypt,
Germany, Hungary, Lithuania, Malaysia, Morocco, Russia, Slove-
nia, South Africa, Tunisia, and Ukraine). Ethical approval for the
study was gained in each country where necessary, in accordance
with the ethical standards laid down in the 1964 Declaration of
Helsinki.
Participating healthcare professionals, including Ear Nose and
Throat Specialists (ENTs), Neurologists, General Practitioners,
and Accident and Emergency Physicians, documented the char-
acteristics and treatment of the next two consecutive patients who
presented with a diagnosis of vertigo of peripheral origin (either as
first diagnosis for the enrolling physician or as a new consultation).
This included patients with other vertigo of peripheral vestibular
origin, BPPV, peripheral vestibular vertigo of unknown pathol-
ogy, or MD. No further inclusion criteria were defined and there
were no specific instructions regarding treatment implementation,
diagnostics, or on-going examination schedule. This was to allow
for non-biased real-world data collection (rather than “research
procedures”). Patient consent was obtained prior to inclusion.
Patients were examined at baseline (Visit 1) and at a sched-
uled 6-month follow-up visit (Visit 2). This report is based on the
analysis of data at Visit 1, focusing on the healthcare resource use
and working status by diagnosis and severity in the 3 months prior
to Visit 1.
Paper-based standardized case report forms (CRFs) were trans-
lated into the local language where applicable. The questions
covered demographic information, medical history, treatments
prior to inclusion in the registry, prescription of a treatment after
enrollment (prescription after enrollment was at the discretion of
the participating physician and was not mandatory), and Clinical
Global Impression score (CGI). The CGI is a three-item observer-
rated scale and is used in this registry to measure illness severity
(CGI-S) (13). CGI-S was assessed at baseline based on the patient’s
description of their condition for the 2 days preceding the visit and
classed as,“normal, not ill at all,”“borderline ill,”“mildly ill,”“mod-
erately ill,”“markedly ill,”“severely ill,”“among the most extremely
ill patients.”
Patients reported the frequency and duration of specific health-
care service use [hospitalization, emergency service use, and gen-
eral practitioner (GP) or specialist consultation] due to vertigo
symptoms during the 3 months preceding Visit 1. Patients also
reported their working status and work days lost in the past
3 months due to vertigo. Healthcare utilization data collected in
this registry is therefore not a long-term indication of usage. Work
productivity data collected in this registry is not a long-term indic-
tor of productivity loss. Furthermore, data were collected to help
understand the real-world complexities of diagnosis, prognosis,
and treatment of vertigo.
STATISTICAL ANALYSIS
Statistical analysis is consistent with the limitations of research in
a naturalistic setting. All summary statistics were performed using
STATA software (special edition 10.0). All analysis variables were
assessed descriptively; discrete data were summarized presenting
counts and percentages. Statistical significance was not determined
in this study. Missing values were not included when calculating
percentages; however, answers of “not applicable” were included.
Only patients who attended Visit 1 were included in the analy-
sis. Continuous data were summarized by the following summary
statistics: number of subjects with non-missing values, number of
subjects with missing values, mean, and standard deviation.
RESULTS
DEMOGRAPHICS
The registry ran from 20th April 2007 to 15th August 2009. A total
of 4,294 patients entered the registry, of which 4,105 reported both
diagnosis and economic data at Visit 1 and were included in this
analysis. A greater proportion of females (65.4%) than males were
included in the registry. Table 1 provides an overview of the study
population at Visit 1. The most common diagnosis was “other ver-
tigo of peripheral vestibular origin” (37.2%), followed by BPPV
(26.9%), peripheral vestibular vertigo of unknown origin (20.5%),
and MD (15.4%).
IMPRESSION OF SEVERITY
At Visit 1, 43% patients were classified by their clinicians as “mod-
erately ill,” with 22.2% “mildly ill,” 20.0% “markedly ill,” 7.4%
“borderline ill,”and 4.1%“severely ill.”This classification of symp-
toms was equal across all age groups and for both genders (data
not shown).
MEDICAL THERAPY BEFORE ENROLLMENT
Reported medicinal products used prior to study enrollment
were betahistine (26.6%), piracetam (11.5%), and gingko biloba
(5.7%). Other therapies included benzodiazepines (4.0%), cal-
cium antagonists (2.2%), neuroleptics (1.9%), antihistamines
(1.7%), and homeopathic medication (1.1%). Co-prescription of
treatments was common. Prescription of a treatment after enroll-
ment to the registry was at the discretion of the participating
physician and was not mandatory.
HEALTHCARE UTILIZATION
Overall patient-reported mean healthcare use due to vertigo over
the previous 3 months was 0.4 (SD± 0.9) utilizations of emer-
gency services, 1.6± 1.8 GP consultations, 1.4± 2.0 specialist con-
sultations (e.g., ear-nose-throat specialist or neurologist), and a
mean of 2.0± 5.4 days spent in hospital due to vertigo. Figure 1
shows the variation in healthcare resource use by age.
The number of GP consultations during the 3 months prior to
Visit 1 was 0.8 in those≤20 years of age and was 2.2 in those aged
>80 years. Those patients between the ages of 51 and 60 years spent
on average 2.4 days in hospital compared to 1.4 in those aged≤20.
Healthcare resource use was also recorded in relation to diag-
nosis. The mean number of hospital days due to vertigo (during
the 3 months before Visit 1) was 2.7 for those diagnosed with
other vertigo of peripheral vestibular origin, compared to 1.4 for
those diagnosed with peripheral vestibular vertigo of unknown
origin (Table 2). The mean number of GP consultations, during
the 3 months prior to Visit 1, was 1.8 for those diagnosed with
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Table 1 | Study population in REVERT registry atVisit 1 (n=4,105).
Variable n (%)
COUNTRY (n=4,105)
Algeria 274 (6.7)
Czech Republic 559 (13.6)
Egypt 168 (4.1)
Germany 99 (2.4)
Hungary 1,320 (32.2)
Lithuania 202 (4.9)
Malaysia 354 (8.6)
Morocco 118 (2.9)
Russia 253 (6.2)
Slovenia 130 (3.2)
South Africa 34 (0.8)
Tunisia 185 (4.5)
Ukraine 409 (10.0)
GENDER (n=4,079)a
Male 1,417 (34.7)
Female 2,662 (65.3)
AGE RANGES,YEARS (n=4,093)b
≤20 29 (0.7)
21–30 181 (4.4)
31–40 437 (10.7)
41–50 799 (19.5)
51–60 1,079 (26.4)
61–70 816 (19.9)
71–80 548 (13.4)
>80 204 (5.0)
DIAGNOSIS (n=4,048)c
Meniere’s disease 625 (15.4)
Benign paroxysmal positional vertigo 1,090 (26.9)
Other vertigo of peripheral vestibular origin 1,504 (37.2)
Peripheral vestibular vertigo of unknown origin 829 (20.5)
SIGNIFICANT MEDICAL HISTORY (n=3,676)d
Cardiac/vascular disease 1,702 (46.3)
Hormonal dysfunction 634 (17.2)
Neurologic disorder 338 (9.2)
Cranial trauma 204 (5.5)
Neoplasm 133 (3.6)
Psychiatric disorder 558 (15.2)
Drug/alcohol abuse 107 (2.9)
an=26 missing data on gender;
bn=12 missing data on age;
cn=57 missing data on diagnosis;
dn=429 missing data on medical history.
peripheral vestibular vertigo of unknown origin, whilst those with
MD and BPPV had on average 1.4 consultations.
The severity of disease was also captured in relation to health-
care resource use in the 3-month period prior to Visit 1 (Figure 2).
Those classed as “severely ill” spent on average 5.4 days in hospi-
tal compared with 0.4 days for patients assessed as “normal, not
at all ill.” Similarly the mean number of consultations with GPs
or Specialists was 0.6 and 0.9 respectively for those assessed as
“normal, not at all ill,” compared to 2.4 consultations (for both
GP and specialists) for those who were assessed as “severely ill”
(Figure 2). Owing to the low number of patients who were “the
most extremely ill”no detailed conclusions can be drawn from this
group.
The healthcare utilization due to vertigo during the 3 months
before Visit 1 was also captured in relation to the different coun-
tries studied (Figure 3). Patients in the Ukraine and Russia spent
on average 7.6 and 5.3 days respectively in hospital due to vertigo
compared with an average of 0.1 days in Egypt. The numbers of
GP consultations ranged from means of 2.6 in Hungary, to 0.5 in
Algeria. The use of emergency services ranged from a mean of 0.6
occasions for Tunisia and the Ukraine to 0.1 occasions in Germany.
CHANGE OF WORK STATUS AND LOST DAYS AT WORK
At Visit 1, about half of all the subjects were in work, either
employed (39.6%) or self-employed (9.1%). Over one third were
retired (36.1%) and 10.8% were unemployed. An undefined status
of “other” was documented for 4.5% of subjects as their current
occupation. Differences were found across countries in terms of
working status. These data indicate the working status during the
3-month period prior to Visit 1 and are not a long-term indication
of status.
A total of 69.8% patients reported they had reduced their work-
load and 63.3% lost working days due to their vertigo, whilst 4.6%
reported changing their job and 5.7% quit work completely as a
consequence of their condition. The impact of age on working
status is shown in Table 3.
Disease severity was also recorded in relation to working status
in the employed population (Table 3). Of those patients assessed as
“severely ill,” 88.7% reduced their workload, 92.5% lost working
days, 18% changed their job, and 22.0% quit work completely
(Table 3). Of those assessed as “normal, not at all ill,” 38.6%
reduced their workload and 31.1% lost working days. No patients
changed or quit their job. The low number of employed patients
who were classed as “the most extremely ill” preclude any detailed
conclusions being drawn from this group. Responses to ques-
tions on working status were not mutually exclusive and multiple
answers were allowed. Finally, Table 4 shows the number of lost
work days in the past 3 months before Visit 1 by country.
DISCUSSION
Naturalistic data on the burden of vertigo are limited, therefore
the aim of the REVERT registry was to prospectively examine,
in a large patient population, the impact of vertigo on work
performance and healthcare utilization.
The results of this registry suggest that in the 13 countries stud-
ied, high frequencies of GP consultations, specialist consultations,
and emergency services usage are likely to impose a considerable
burden on healthcare providers. Furthermore, these data suggest
that healthcare use may be influenced by increasing age and disease
severity; therefore, treatments that can alter the natural course of
the disease may lead to reductions in the burden of disease even if
they do not provide a cure.
Due to the unique nature of our study and its observational
design, we were not able to perform comparisons between patients
with vertigo on one side and healthy patients on the other side.
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FIGURE 1 | Healthcare utilization by patients with vertigo during the 3months beforeVisit 1 by age group.
Table 2 | Healthcare utilization during the 3months beforeVisit 1 by diagnosis.
Diagnosis Emergency service use GP consultations Specialist consultations Days spent in hospital
mean (± SD)
Meniere’s disease 0.53 (0.99) 1.36 (1.83) 1.46 (1.45) 1.63 (4.80)
Benign paroxysmal positional vertigo 0.40 (0.85) 1.42 (1.75) 1.37 (3.06) 1.73 (5.73)
Other vertigo of peripheral vestibular origin 0.41 (0.82) 1.78 (1.88) 1.46 (1.62) 2.65 (5.82)
Peripheral vestibular vertigo of unknown origin 0.40 (0.81) 1.83 (1.72) 1.14 (1.21) 1.37 (3.89)
MD, Meniere’s disease; BPPV, benign paroxysmal positional vertigo; GP, general practitioner; SD, standard deviation.
FIGURE 2 | Healthcare utilization by patients with vertigo during the 3months beforeVisit 1 by illness severity.
Also, to the best of our knowledge, there are no similar studies
in the literature which would allow a comparison of our findings
with previously published data. However, the overall findings of
this study support those of other local-level studies. For example,
a recent study on the epidemiology of vertigo in Taiwan found that
vertigo is a major health burden among the general adult popu-
lation and tends to recur, particularly among older women (14).
In the United States, dizziness is estimated to account for 5.0%
of walk-in clinic visits and there are 2.6 million visits to emer-
gency departments due to dizziness annually, which accounted
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FIGURE 3 | Healthcare utilization by patients with vertigo during the 3months beforeVisit 1 by country.
for 3.3% of all emergency department visits during 1993–2005
(15). In addition, Neuhauser et al. evaluated the burden of ver-
tigo in Germany in a study of 1,003 patients (9). The results from
this study are in line with these findings and demonstrate that
patients suffering from vertigo frequently consulted medical prac-
titioners, often required sick leave and had interruptions to their
daily activities (9). While this study indicated that both dizziness
and vertigo are frequent symptoms in general practice and inflict
a considerable health care burden, it is also noted that vertigo
disorders are associated with lower quality of life compared to
control subjects. The authors also indicated that the underestima-
tion of dizziness and vertigo symptoms and resultant effects, are
reflected in the fact that large percentages of the underlying disor-
ders remain under-diagnosed and, therefore, are presumed to be
insufficiently treated.
From the perspective of those individuals who were in employ-
ment, data from the REVERT registry highlight the impact of
vertigo on work performance. For example, 70.0% of the work-
ing population had reduced their workload and 63.0% had lost
working days in the 3 months before the baseline visit. On aver-
age, as many as 14 working days were lost due to vertigo during
the prior 3 months among those in employment. The results
suggest that work performance and employment status are also
affected by the specific diagnosis and severity of vertigo symp-
toms in patients who are employed, although differences exist
presumably due, at least in part, to variances in the social care
systems of the respective countries. These results are consis-
tent with the limited published data, with Skøien et al. report-
ing that vertigo symptoms can lead to long-term work absence
and an increased risk of requiring a disability pension later in
life (5).
When there is limited evidence on the healthcare- and work-
burden of disease, it is standard practice to compare a condition
to a disease with a similar progression. Aspects of vertigo are mir-
rored in other conditions where low mortality but high morbidity
translates into a negative impact on daily activities. For example,
people with chronic lower back pain experience persistent dis-
comfort for which temporary pain relief is often ineffective and
insufficient. This leads to a decrease in productivity due to absen-
teeism or presenteeism which translates into high indirect costs
(i.e., to society and employers) (15, 16). Furthermore, in the USA,
back pain is one of the most frequent reasons for visits to physicians
and hospitalizations, leading to a high burden on the healthcare
system (16).
Registry-based, observational studies have several well-
documented limitations. The drawbacks of uncontrolled real-
world evidence include insufficient quality and depth to data,
potential sources of bias, and significant missing data. For exam-
ple, in this study healthcare resource use and working status are
based on patient memory which is subject to recall bias. These
answers were not cross-checked with medical and social records,
and the diagnoses were not universally validated, which could
mean that these differed between both institutions and countries.
There is also no clarity on diagnosis definitions, which could mean
that these differed by center and country: in order to try to at
least partly overcome this limitation, we created the diagnostic
category “Other vertigo of peripheral vestibular origin.” This cat-
egory might lack specificity, but has the advantage of avoiding an
inconsistent attribution of patients to various, not well defined
diagnostic categories.
Participating countries and centers were selected based on will-
ingness to contribute and therefore do not provide global coverage
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Table 3 | Impact of vertigo on the working status of the employed population, by age group, diagnosis, and illness severity in the 3months
beforeVisit 1 (% of employed patients).
Patients, n Reduced workload Loss of working days Change of job Quit job
% of employed patients
AGE RANGES,YEARS
≤20 10 70.0 60.0 0.0 0.0
21–30 100 64.7 63.6 5.3 7.4
31–40 292 72.4 64.1 5.9 6.3
41–50 533 68.0 64.9 5.4 5.4
51–60 567 70.8 61.6 3.5 5.9
61–70 102 72.7 63.7 3.0 4.0
≥70 11 60.0 45.5 0.0 9.1
DIAGNOSIS
MD 269 72.0 69.7 9.2 8.9
BPPV 462 68.1 60.2 4.0 6.5
Other vertigo of peripheral vestibular origin 593 72.8 65.3 3.3 4.7
Peripheral vestibular vertigo of unknown origin 288 64.2 56.6 2.8 3.2
GLOBAL IMPRESSION OF SEVERITY
Normal, not all ill 45 38.6 31.1 0.0 0.0
Borderline ill 138 46.3 37.2 1.5 1.5
Mildly ill 410 51.7 41.8 0.7 1.7
Moderately ill 612 76.7 70.0 4.7 5.5
Markedly ill 342 90.7 87.6 9.2 11.2
Severely ill 53 88.7 92.5 18.0 22.0
The most extremely ill 5 80.0 40.0 0.0 20.0
MD, Meniere’s disease; BPPV, benign paroxysmal positional vertigo.
Table 4 | Mean number of lost work days among employed patients in
the past 3months beforeVisit 1 by country.
Country Patients, n Lostworkdays in thepast
3months beforeVisit 1
Mean (SD) Min, Max
Algeria 68 11.2 (9.3) 1, 60
Czech Republic 132 13.1 (14.6) 1, 90
Egypt 48 9.5 (13.5) 1, 90
Germany 22 26.7 (39.5) 1, 90
Hungary 161 13.2 (10.9) 2, 75
Lithuania 73 15.7 (17.0) 1, 90
Malaysia 79 8.7 (16.1) 1, 90
Morocco 28 13.9 (16.6) 2, 90
Russia 131 13.7 (10.6) 1, 66
Slovenia 36 15.8 (15.5) 1, 84
South Africa 16 9.7 (14.5) 1, 60
Tunisia 56 9.5 (12.1) 1, 90
Ukraine 132 15.8 (15.4) 1, 90
SD, standard deviation.
and do not necessarily provide a representative sample of each
country, which is a general limitation of research in a naturalistic
registry setting. For example, Hungary recruited far more patients
than any other country; such disparities in recruitment confer
the risk of a non-representative patient population. These dispar-
ities might also have led to some inconsistencies in the results:
for example, we observed major differences in the amount of lost
working days across countries. Furthermore, this was a multi-
national study involving countries with different cultures and
approaches to health and social care,and this must be considered as
potentially contributing to the heterogeneity in the data. Despite
these drawbacks, registries studies, including this one, generate
data of vast potential and are important for collecting, classify-
ing, and linking disease-specific information. While clinical trials
give generate data in controlled conditions, registries can provide
real-world data on the natural history of disease, in a more diverse
patient population over a long-period (16).
In conclusion, the results from the REVERT registry provide
some valuable insight into the potential personal, societal, and
economic burden of vertigo. This may be of particular relevance
in countries where a societal view of healthcare is applied since
an improvement in the management of vertigo patients may have
effects not only on the healthcare system but on society overall.
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